ID   SK-MEL-2
AC   CVCL_0069
SY   SK-Mel-2; SK-Mel 2; SK-mel-2; SK-MEL2; SK.MEL.2; SK Mel 2; SK MEL 2; SKMEL-2; SKMEL2; SKmel2; SK-ML2; SKml2
DR   BTO; BTO:0003476
DR   CLO; CLO_0009041
DR   EFO; EFO_0002079
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-68
DR   BioGRID_ORCS_Cell_line; 1012
DR   BioSample; SAMN03471882
DR   BioSample; SAMN03472752
DR   BioSample; SAMN05292464
DR   BioSample; SAMN10988256
DR   cancercelllines; CVCL_0069
DR   Cell_Model_Passport; SIDM00082
DR   CGH-DB; 9322-4
DR   ChEMBL-Cells; CHEMBL3307743
DR   ChEMBL-Targets; CHEMBL614917
DR   CLS; 300423
DR   Cosmic; 724824
DR   Cosmic; 875885
DR   Cosmic; 897468
DR   Cosmic; 905235
DR   Cosmic; 905955
DR   Cosmic; 974073
DR   Cosmic; 974257
DR   Cosmic; 1006555
DR   Cosmic; 1022288
DR   Cosmic; 1044266
DR   Cosmic; 1045411
DR   Cosmic; 1067222
DR   Cosmic; 1092632
DR   Cosmic; 1132585
DR   Cosmic; 1155283
DR   Cosmic; 1175871
DR   Cosmic; 1303053
DR   Cosmic; 1305367
DR   Cosmic; 1458964
DR   Cosmic; 1459662
DR   Cosmic; 1477419
DR   Cosmic; 1669129
DR   Cosmic; 1995633
DR   Cosmic; 1998475
DR   Cosmic; 2159450
DR   Cosmic; 2479250
DR   Cosmic-CLP; 905955
DR   DepMap; ACH-001190
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 905955
DR   GEO; GSM2109
DR   GEO; GSM50204
DR   GEO; GSM50266
DR   GEO; GSM188225
DR   GEO; GSM188255
DR   GEO; GSM188314
DR   GEO; GSM743467
DR   GEO; GSM750824
DR   GEO; GSM799356
DR   GEO; GSM799419
DR   GEO; GSM847115
DR   GEO; GSM844688
DR   GEO; GSM844689
DR   GEO; GSM887585
DR   GEO; GSM888668
DR   GEO; GSM1153426
DR   GEO; GSM1181281
DR   GEO; GSM1181359
DR   GEO; GSM1670437
DR   GEO; GSM1671997
DR   GEO; GSM1672003
DR   GEO; GSM1672044
DR   GEO; GSM1672075
DR   GEO; GSM1672083
DR   GEO; GSM1672088
DR   GEO; GSM1672104
DR   GEO; GSM1672117
DR   GEO; GSM1672126
DR   GEO; GSM2124650
DR   IARC_TP53; 18086
DR   KCLB; 30068
DR   LINCS_LDP; LCL-1256
DR   NCI-DTP; SK-MEL-2
DR   PharmacoDB; SKMEL2_1394_2019
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD030206
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0069
DR   PubChem_Cell_line; CVCL_0069
DR   SKY/M-FISH/CGH; 2820
DR   Wikidata; Q54953905
RX   DOI=10.1007/978-1-4757-1647-4_5;
RX   DOI=10.1007/BF00199208;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=2041050;
RX   PubMed=2784858;
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=7718330;
RX   PubMed=7999427;
RX   PubMed=8755562;
RX   PubMed=10700174;
RX   PubMed=12068308;
RX   PubMed=14871852;
RX   PubMed=15467732;
RX   PubMed=15748285;
RX   PubMed=17088437;
RX   PubMed=18277095;
RX   PubMed=19372543;
RX   PubMed=19727395;
RX   PubMed=20164919;
RX   PubMed=21725359;
RX   PubMed=21912889;
RX   PubMed=22068913;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=23285177;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24279929;
RX   PubMed=24576830;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25728708;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27533468;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.synapse.org/#!Synapse:syn31544462
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=45
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/human-melanoma-cell-line-sk-mel-2
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 779.
CC   Population: Caucasian.
CC   Doubling time: 32 hours (PubMed=7718330); 45.5 hours (NCI-DTP=SK-MEL-2); ~56 hours (PBCF).
CC   HLA typing: A*03,26; B*35,38; C*04,12:03:01; DPB1*02:01:02,04:01; DQB1*03:01:01,06:03; DRB1*04:02,13:01:01 (PubMed=15748285).
CC   HLA typing: A*03:01,26:01; B*35:08,38:01; C*04:01,12:03; DQA1*03:02,03:02; DQB1*06:11,06:11; DRB1*04:02,13:01 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (PubMed=12068308; PubMed=15467732; PubMed=17088437; PubMed=21725359; PubMed=24576830; PubMed=25728708; PubMed=27533468).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Heterozygous (PubMed=17088437; PubMed=18277095; PubMed=21912889; PubMed=27533468).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.43%; Native American=0%; East Asian, North=2.36%; East Asian, South=1.87%; South Asian=7.21%; European, North=28.23%; European, South=58.89% (PubMed=30894373).
CC   Misspelling: SKm12; Note=Occasionally.
CC   Derived from site: Metastatic; Thigh, skin; UBERON=UBERON_0004262.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=19372543; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11 (Cosmic-CLP; PubMed=19372543; PubMed=25877200)
ST   D13S317: 10,11 (ATCC)
ST   D16S539: 8,9
ST   D18S51: 15,16
ST   D19S433: 12,15
ST   D21S11: 29,30
ST   D3S1358: 14,16
ST   D5S818: 11,12,13 (ATCC)
ST   D5S818: 12,13 (Cosmic-CLP; PubMed=19372543; PubMed=25877200)
ST   D7S820: 11,12
ST   D8S1179: 12,13
ST   FGA: 19,25
ST   Penta D: 10,15
ST   Penta E: 7,16
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 16,17 (ATCC)
ST   vWA: 17 (Cosmic-CLP; PubMed=19372543; PubMed=25877200)
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   60Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 45
//
RX   DOI=10.1007/978-1-4757-1647-4_5;
RA   Fogh J., Trempe G.L.;
RT   "New human tumor cell lines.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975).
//
RX   DOI=10.1007/BF00199208;
RA   Bruggen J., Sorg C., Macher E.;
RT   "Membrane associated antigens of human malignant melanoma V:
RT   Serological typing of cell lines using antisera from nonhuman
RT   primates.";
RL   Cancer Immunol. Immunother. 5:53-62(1978).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=2784858; DOI=10.1073/pnas.86.8.2804;
RA   Knuth A., Wolfel T., Klehmann E., Boon T.,
RA   Meyer zum Buschenfelde K.-H.;
RT   "Cytolytic T-cell clones against an autologous human melanoma:
RT   specificity study and definition of three antigens by
RT   immunoselection.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:2804-2808(1989).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H;
RA   Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J.,
RA   McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M.,
RA   van Zijl P.;
RT   "Resistance mechanisms determining the in vitro sensitivity to
RT   paclitaxel of tumour cells cultured from patients with ovarian
RT   cancer.";
RL   Eur. J. Cancer 31:230-237(1995).
//
RX   PubMed=7999427; DOI=10.1016/0959-8049(94)90188-0;
RA   Marshall E.S., Matthews J.H.L., Shaw J.H.F., Nixon J., Tumewu P.,
RA   Finlay G.J., Holdaway K.M., Baguley B.C.;
RT   "Radiosensitivity of new and established human melanoma cell lines:
RT   comparison of [3H]thymidine incorporation and soft agar clonogenic
RT   assays.";
RL   Eur. J. Cancer 30:1370-1376(1994).
//
RX   PubMed=8755562; DOI=10.1073/pnas.93.15.7832;
RA   Liu D.-C., Pearlman E., Diaconu E., Guo K., Mori H., Haqqi T.,
RA   Markowitz S.D., Willson J.K.V., Sy M.-S.;
RT   "Expression of hyaluronidase by tumor cells induces angiogenesis in
RT   vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:7832-7837(1996).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=18277095; DOI=10.4161/cbt.7.5.5712;
RA   Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.;
RT   "Analysis of p53 mutation status in human cancer cell lines: a
RT   paradigm for cell line cross-contamination.";
RL   Cancer Biol. Ther. 7:699-708(2008).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=19727395; DOI=10.1371/journal.pone.0006888;
RA   Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R.,
RA   Finn S.P., Loda M., Mahmood U., Ramaswamy S.;
RT   "Systems-level modeling of cancer-fibroblast interaction.";
RL   PLoS ONE 4:E6888-E6888(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=21912889; DOI=10.1007/s10637-011-9744-z;
RA   Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A.,
RA   Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P.,
RA   Ding A., Baguley B.C.;
RT   "Therapeutic reactivation of mutant p53 protein by quinazoline
RT   derivatives.";
RL   Invest. New Drugs 30:2035-2045(2012).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23285177; DOI=10.1371/journal.pone.0052760;
RA   Schayowitz A.B., Bertenshaw G.P., Jeffries E., Schatz T., Cotton J.,
RA   Villanueva J., Herlyn M., Krepler C., Vultur A., Xu W., Yu G.H.,
RA   Schuchter L.M., Clark D.P.;
RT   "Functional profiling of live melanoma samples using a novel automated
RT   platform.";
RL   PLoS ONE 7:E52760-E52760(2012).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25728708; DOI=10.1111/pcmr.12364;
RA   Vogel C.J., Smit M.A., Maddalo G., Possik P.A., Sparidans R.W.,
RA   van der Burg S.H., Verdegaal E.M.E., Heck A.J.R., Samatar A.A.,
RA   Beijnen J.H., Altelaar A.F.M., Peeper D.S.;
RT   "Cooperative induction of apoptosis in NRAS mutant melanoma by
RT   inhibition of MEK and ROCK.";
RL   Pigment Cell Melanoma Res. 28:307-317(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27533468; DOI=10.1080/15384101.2016.1208862;
RA   Malka-Mahieu H., Girault I., Rubington M., Leriche M., Welsch C.,
RA   Kamsu-Kom N., Zhao Q., Desaubry L., Vagner S., Robert C.;
RT   "Synergistic effects of eIF4A and MEK inhibitors on proliferation of
RT   NRAS-mutant melanoma cell lines.";
RL   Cell Cycle 15:2405-2409(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//